Yuko Nagayasu
Papers
1
Total Citations
4
H-Index
1
About
Dr. Yuko Nagayasu is a clinical researcher whose work focuses on integrative oncology, particularly the role of natural compounds in prostate cancer management. Her major contribution lies in pioneering the investigation of luteolin—a dietary flavonoid—as a potential chemopreventive and chemotherapeutic agent for prostate cancer, especially for patients under active surveillance. Her most cited paper, "Preliminary Evidence on Safety and Clinical Efficacy of Luteolin for Patients With Prostate Cancer Under Active Surveillance" (2025, 4 citations), provides early clinical evidence addressing the critical need for effective, low-toxicity interventions to delay disease progression and the re-emergence of cancer following androgen deprivation therapy. This work builds on her prior preclinical studies demonstrating luteolin’s chemopreventive potential, bridging a gap between laboratory findings and patient care. While her citation count is modest, reflecting the novelty of her clinical research, her work is notable for its translational impact—offering a promising, plant-based strategy for men seeking alternatives to aggressive treatment. Dr. Nagayasu’s research holds significant promise for improving quality of life and outcomes in prostate cancer patients.
Research Focus
Key Achievements
Top Papers
- 1